Caring for the critically ill patient. High-dose antithrombin III in severe sepsis: a randomized controlled trial.
By B. Warren, A. Eid, P. Singer, S. Pillay, Rcs, P. Carl, I. Novak, Pavel Chalupa, A. Atherstone, I. Pénzes and 8 more. Journal of the American Medical Association (JAMA), 2001
645 citations recorded by the source corpus.
View Paper: https://www.semanticscholar.org/paper/1900fee90cd87b771074df0b1268197cd338c107
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
- D. Stearns-Kurosawa
- D. Remick
- M. Osuchowski
- M. Levi
- T. van der Poll
- Catherine Valentine
- S. Kurosawa
- R. E. Goyette
Citations in the corpus
- The interactions between inflammation and coagulation (2005, background): “Of interest, antithrombin (Warren et al, 2001) and TFPI both failed large randomised clinical trials (Abraham et al, 2003).”
- Guidelines for the diagnosis and management of disseminated intravascular coagulation (2009, unknown): “A large-scale multicentre randomised controlled trial to directly assess the effect of antithrombin concentrate on mortality in septic patients also showed no significant reduction in those treated with antithrombin concentrate (Warren et al , 2001).”
- The Pathogenesis of Sepsis (2011, background): “This ongoing debate is fueled by the success (53), failure (54– 56), or uncertain ability (57) of anticoagulant compounds to alter 28-day all-cause mortality in sepsis clinical trials.”
- Hematologic changes in sepsis and their therapeutic implications. (2004, methodology): “ALTERATIONS OF PLATELETS IN SEPSIS Thrombocytopenia is a frequent accompaniment of critical illness and is commonly employed in clinical trials of severe sepsis therapies as a marker of hematologic organ system dysfunction.(35,36) In the ICU setting, platelet counts < 100,000/mm(3) (< 100 10(9)/L) a”
- Inflammation and coagulation (2010, background): “However, a largescale, multicenter, randomized, controlled trial to directly address this issue showed no significant reduction in mortality of patients with sepsis who were treated with antithrombin concentrate (118).”